<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Morphea on Rheumatology Digest</title><link>https://rheumatologydigest.org/tags/morphea/</link><description>Recent content in Morphea on Rheumatology Digest</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Tue, 30 Jun 2026 05:00:00 +0530</lastBuildDate><atom:link href="https://rheumatologydigest.org/tags/morphea/index.xml" rel="self" type="application/rss+xml"/><item><title>A Practical Clinical Approach to Morphea (Localized Scleroderma)</title><link>https://rheumatologydigest.org/posts/morphea-diagnosis-management/</link><pubDate>Tue, 30 Jun 2026 05:00:00 +0530</pubDate><guid>https://rheumatologydigest.org/posts/morphea-diagnosis-management/</guid><description>A 2026 practical review of morphea (localized scleroderma) across age groups — an organ-sparing autoimmune skin disease distinct from systemic sclerosis. Covers classification, the high-stakes subtypes (pansclerotic, facial linear), activity-vs-damage assessment, and management anchored on long-course methotrexate plus a steroid bridge, where depth and site dictate aggressiveness.</description></item></channel></rss>